Literature DB >> 26602777

Trabectedin is an effective second-line treatment in soft tissue sarcoma patients.

C Peugniez1, S Cousin2, N Penel3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26602777     DOI： 10.1093/annonc/mdv585

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  2 in total

1.  Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.

Authors:  R L Jones; G D Demetri; S M Schuetze; M Milhem; A Elias; B A Van Tine; J Hamm; S McCarthy; G Wang; T Parekh; R Knoblauch; M L Hensley; R G Maki; S Patel; M von Mehren
Journal:  Ann Oncol       Date:  2018-09-01       Impact factor: 32.976

Review 2.  Managing sarcoma: where have we come from and where are we going?

Authors:  Jenna S Bleloch; Reyna D Ballim; Serah Kimani; Jeannette Parkes; Eugenio Panieri; Tarryn Willmer; Sharon Prince
Journal:  Ther Adv Med Oncol       Date:  2017-09-20       Impact factor: 8.168
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.